BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 37093458)

  • 21. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
    Wang B; Wang J; Huang SQ; Su HH; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
    Lehtinen T; Tolonen A; Turpeinen M; Uusitalo J; Vuorinen J; Lammintausta R; Pelkonen O; Scheinin M
    Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
    Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
    Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
    Heinig R; Gerisch M; Bairlein M; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):433-444. PubMed ID: 32125665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 and its role in veterinary drug interactions.
    Trepanier LA
    Vet Clin North Am Small Anim Pract; 2006 Sep; 36(5):975-85, v. PubMed ID: 16984823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.
    Agarwal S; Agarwal SK
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):427-440. PubMed ID: 32918656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: Report of two cases
.
    Shibata S; Takahashi H; Baba A; Takeshita K; Atsuda K; Matsubara H; Echizen H
    Int J Clin Pharmacol Ther; 2017 May; 55(5):449-452. PubMed ID: 28157069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
    Wang X; Dowty ME; Wouters A; Tatulych S; Connell CA; Le VH; Tripathy S; O'Gorman MT; Winton JA; Yin N; Valdez H; Malhotra BK
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):419-429. PubMed ID: 35226304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E; Andersson TB; Frison L; Thuresson A; Johansson S; Eriksson-Lepkowska M; Larsson M; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):765-77. PubMed ID: 12846597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies.
    Donato MT; Castell JV
    Clin Pharmacokinet; 2003; 42(2):153-78. PubMed ID: 12537515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro.
    Shimokawa Y; Sasahara K; Yoda N; Mizuno K; Umehara K
    Biol Pharm Bull; 2014; 37(11):1727-35. PubMed ID: 25366478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
    Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
    Barry M; Gibbons S; Back D; Mulcahy F
    Clin Pharmacokinet; 1997 Mar; 32(3):194-209. PubMed ID: 9084959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes.
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Dec; 28(6):493-6. PubMed ID: 14651673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.